Results 221 to 230 of about 45,526 (248)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
openaire  

Some of the next articles are maybe not open access.

Related searches:

Model Mice for BCR/ABL-Positive Leukemias

Blood Cells, Molecules, and Diseases, 2001
p210bcr/abl is detected in almost all chronic myelogenous leukemia (CML) patients and a significant number of acute lymphoblastic leukemia (ALL) cases. It is generated by a reciprocal chromosomal translocation, t(9;22) (q34;q11), and the enhanced kinase activity of the protein is believed to be implicated in the pathogenesis of the diseases. To examine
H, Honda, H, Hirai
openaire   +2 more sources

Management of Bcr–Abl-positive leukemias with dasatinib

Expert Review of Anticancer Therapy, 2007
Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized,
openaire   +2 more sources

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias

Investigational New Drugs, 2012
Effective inhibition of BCR-ABL tyrosine kinase activity with Imatinib represents a breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, more than 30 % of patients with CML in chronic phase do not respond adequately to Imatinib and the drug seems not to affect the quiescent pool of BCR-ABL positive leukemic stem and ...
Ziegler, P, Chahoud, T, Wilhelm, T, Pällman, N, Braig, M, Wiehle, V, Ziegler, S, Schröder, M, Meier, C, Kolodzik, A, Rarey, M, Panse, J, Hauber, J, Balabanov, S, Brümmendorf, T H   +14 more
openaire   +2 more sources

Current and future management of Ph/BCR-ABL positive ALL

Expert Review of Anticancer Therapy, 2014
Following the introduction of targeted therapy with tyrosine kinase inhibitors (TKI) at the beginning of the past decade, the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved. Presently, the use of refined programs with first/second generation TKI's and chemotherapy together with
Elena, Maino, Rosaria, Sancetta, Piera, Viero, Silvia, Imbergamo, Anna Maria, Scattolin, Michele, Vespignani, Renato, Bassan   +6 more
openaire   +2 more sources

Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia

International Journal of Hematology, 2016
Dasatinib, a second-generation tyrosine kinase inhibitor, is a highly effective treatment for Bcr-Abl-positive leukemia. However, the mechanism by which dasatinib induces cell death is unclear, particularly in vivo. Autophagy is a lysosomal degradation mechanism essential for cell survival and differentiation.
Makiko, Morita, Yoko, Nishinaka, Itaru, Kato, Satoshi, Saida, Hidefumi, Hiramatsu, Yasuhiko, Kamikubo, Toshio, Heike, Tatsutoshi, Nakahata, Souichi, Adachi   +8 more
openaire   +2 more sources

Function of STAT5 Isoforms in Bcr-Abl Positive Cells

Blood, 2011
Abstract Abstract 1313 Chronic myeloid leukemia (CML) is caused by expression of the BCR-ABL oncogene product which exerts constitutive tyrosine kinase activity. Specific inhibition of the BCR-ABL tyrosine kinase activity by small tyrosine kinase inhibitors (TKIs) is now well established as initial therapy for newly ...
Michael Schaller-Schoenitz, Iris Dallmann, Arnold Ganser, Michaela Scherr, Matthias Eder   +4 more
openaire   +1 more source

Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells

Genes, Chromosomes and Cancer, 2006
AbstractBACH2 is a B‐cell‐specific transcription repressor and is also know as a tumor suppressor in B cell malignancy. Expression of BACH2 is induced in BCR‐ABL positive lymphoid cell lines including BV173 by imatinib, a molecular targeting agent for the treatment of chronic myeloid leukemia (CML).
Atsushi, Ono, Kazuteru, Kono, Dai, Ikebe, Akihiko, Muto, Jiying, Sun, Masao, Kobayashi, Kazuhiro, Ueda, Junia V, Melo, Kazuhiko, Igarashi, Satoshi, Tashiro   +9 more
openaire   +2 more sources

Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation

Biochemical Pharmacology, 2018
Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) are hematopoietic malignancies caused by the constitutive activation of BCR-ABL tyrosine kinase. Although direct BCR-ABL inhibitors, such as imatinib, were initially successful in the treatment of leukemia, many patients developed drug resistance over time due to the gatekeeper ...
Yuki, Uchihara, Kenji, Tago, Hidetoshi, Taguchi, Yuji, Narukawa, Fumiyuki, Kiuchi, Hiroomi, Tamura, Megumi, Funakoshi-Tago   +6 more
openaire   +2 more sources